Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.48 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.48 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.48 |
| ▸ | NAMPT | P43490 | 11/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4882042 | 0.83 | TAS1R3 (0.67) | SMN1; SMN2LMNAPOLBTAS1R3TAS1R1 | |
| SCHEMBL4874554 | 0.72 | SMN1; SMN2 (0.69) | SMN1; SMN2LMNAPOLBTAS1R3TAS1R1 | |
| SCHEMBL14066260 | 0.71 | DPP8 (0.40) | NAMPT | |
| SCHEMBL4881917 | 0.71 | DPP8 (0.40) | NAMPT | |
| SCHEMBL4881919 | 0.71 | DPP8 (0.40) | NAMPT | |
| SCHEMBL4880755 | 0.69 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAPOLBTAS1R3TAS1R1 | |
| SCHEMBL22169249 | 0.69 | DPP8 (0.53) | NAMPT | |
| SCHEMBL5424658 | 0.69 | SMN1; SMN2 (0.56) | SMN1; SMN2LMNANPSR1 | |
| SCHEMBL5432819 | 0.68 | SMN1; SMN2 (0.55) | SMN1; SMN2LMNAPOLBNPSR1 | |
| SCHEMBL14119932 | 0.68 | LMNA (1.00) | SMN1; SMN2LMNAPOLBNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080234252-A1 | Compounds Useful in Therapy | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234252-A1 | Compounds Useful in Therapy | AVPR1A, AVPR1B, AVPR2 | SMN1; SMN2 2757/4885LMNA 1476/4885POLB 2702/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.